Invivyd (IVVD) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Invivyd (IVVD) over the past year, gaining 74.5% versus a loss of 55.3%. Over five years, STRO leads with a -92.3% price change compared with -97.8% for IVVD. Sutro Biopharma is the larger company by market cap ($243.1 million vs $214.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | STRO |
|---|---|---|
| Share price | $0.7286 | $14.66 |
| Market cap | $214.76M | $243.08M |
| 1-day change | -9.65% | +1.45% |
| YTD return | -70.50% | +26.71% |
| 1-year return | -55.30% | +74.52% |
| 5-year return | -97.75% | -92.28% |
| EPS (TTM) | $-0.33 | $-17.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $43.85 |
| 52-week low | $0.528 | $7.15 |
| Distance from 52-week high | -76.27% | -66.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1272.50% | +222.17% |
| Average volume | 4.70M | 289.73K |
| Shares outstanding | 294.76M | 16.58M |
| Employees | 122 | 128 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed IVVD by 129.8 percentage points over the past year.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Healthcare · Biotechnology · 122 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Healthcare · Biotechnology · 128 employees
IVVD vs STRO FAQ
Which is bigger, Invivyd or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $243.08M compared with $214.76M for Invivyd (IVVD).
Which stock has performed better over the past year, IVVD or STRO?
STRO returned +74.52% over the past 12 months, compared with -55.30% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.